SCHEMBL4476430

SCHEMBL4476430

CC(C)(C)OC(=O)NC1CN(c2nc(Cl)ccc2C(F)(F)F)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.46
JAK3 P52333 1/20 0.43
BTK Q06187 1/20 0.43
DRD2 P14416 2/20 0.40
MAP4K4 O95819 2/20 0.40
DRD3 P35462 1/20 0.40
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
SUV39H2 Q9H5I1 5/20 0.39
EIF2AK4 Q9P2K8 1/20 0.39
NSD2 O96028 1/20 0.39
SYK P43405 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ITGB2 P05107 1/20 0.39
ICAM1 P05362 1/20 0.39
ITGAL P20701 1/20 0.39
PIM1 P11309 1/20 0.38
PIM3 Q86V86 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28930757 0.91 PDE10A (0.49) PDE10AJAK3BTKMAP4K4CKS1B
SCHEMBL28930758 0.91 PDE10A (0.49) PDE10AJAK3BTKMAP4K4CKS1B
SCHEMBL4485720 0.83 PDE10A (0.49) PDE10AJAK3BTKMAP4K4CKS1B
SCHEMBL6142899 0.81 GRM2 (0.38) NSD2
SCHEMBL4471437 0.80 PDE10A (0.50) PDE10AJAK3BTKMAP4K4CKS1B
SCHEMBL15401351 0.76 BTK (0.55) PDE10AJAK3BTKMAP4K4SUV39H2
SCHEMBL21227858 0.75 PDE10A (0.48) PDE10AJAK3BTKMAP4K4CKS1B
SCHEMBL3820924 0.75 CKS1B (0.53) PDE10AJAK3BTKDRD2MAP4K4
SCHEMBL1351743 0.74 PDE10A (0.55) PDE10ACKS1BSKP1SKP2SYK
SCHEMBL1351739 0.74 PDE10A (0.55) PDE10ACKS1BSKP1SKP2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514562-B2 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain GLAXO GROUP LIMITED (GB) 2009-04-07 US disclosed
US-20060276447-A1 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain GLAXO GROUP LIMITED (GB) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276447-A1 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain TRPV1, UTS2R, OPRL1 PDE10A 509/4885JAK3 2421/4885BTK 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.